Hjem › Nyrekreft (nyrecellekarcinom) › Arizona
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Arizona
22 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i Arizona.
Byer i Arizona
Offisiell studietekst (engelsk)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Mayo Clinic Arizona, Phoenix
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07419841A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University of Arizona Cancer Center, Tucson
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #67, Phoenix
- Exelixis Clinical Site #1, Tucson
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Mayo Clinic Hospital in Arizona, Phoenix
- Mayo Clinic in Arizona, Scottsdale
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- City of Hope Phoenix, Goodyear
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07594106DESTINY-PANTUMOUR04
- Research Site, Bullhead City
- Research Site, Casa Grande
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04981119Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Kingman Regional Medical Center, Kingman
- Mayo Clinic Hospital in Arizona, Phoenix
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Mayo Clinic Building- Phoenix, Phoenix
- Mayo Clinic Arizona, Scottsdale
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07227415ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06661720A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- HonorHealth Research Institute, Scottsdale
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07636785Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Phoenix
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05433142A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Banner MD Anderson Cancer Center, Gilbert
- Mayo Clinic, Phoenix
- University of Arizona, Tucson
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT03972657KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
- University of Arizona, Tucson
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jun. 2026 · NCT06026410Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 4. jun. 2026 · NCT04777994Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Arizona, Phoenix
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. mar. 2026 · NCT06349642A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Banner MD Anderson Cancer Center, Gilbert
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT06682793Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Banner MD Anderson Cancer Center, Gilbert
- Kingman Regional Medical Center, Kingman
- Banner University Medical Center - Tucson, Tucson
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04510597A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Mayo Clinic in Arizona, Scottsdale
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. nov. 2024 · NCT05824975Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- HonorHealth Research Institute, Scottsdale
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. nov. 2024 · NCT04787042Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.